Berkshire Local Peer Support Group
Monday 12 October 2026, 7pm - 8pm - via Zoom - Please come and join facilitator James and the Berkshire group for their latest online social catch up.
Search results
Monday 12 October 2026, 7pm - 8pm - via Zoom - Please come and join facilitator James and the Berkshire group for their latest online social catch up.
Saturday 8 August 2026, 12.30pm - 6.30pm - In-person - Please come and join Rachael and the group at The Waldorf pub in Manchester for their latest social get together including guest speakers Katy Whitwell & Lisa Howell from the RNIB's ECLO service.
Tuesday 22 September 2026, 7.00pm - 8.00pm - via Zoom - Please come and join facilitator Suzanne and the group for their latest online catch up where we are pleased to welcome our guest speaker Tricia Sail, winner of BBC's Race Across the World 2023.
It has recently been announced that Meira-GTx, who originally developed bota-vec and collaborated with J&J during its early clinical trials, have entered into an asset purchase agreement with J&J to acquire bota-vec and progress the program towards global regulatory filings for approval.
Tuesday 10 November 2026, 7.00pm - 8.00pm - via Zoom - Please come and join facilitator Stuart and the group for their latest online meeting where we are delighted to welcome our guest speaker Anita Davies, Sight Loss Engagement Manager at WCB.
On a typical week in the stem cell lab there are many different experiments going on. Different people work on their individual projects, but we often collaborate to share ideas and help each other.
Whether you are looking for practical information or emotional support, online, by phone or face-to-face, we’re here to help.
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Tuesday 29 September 2026, 7.00pm - 8.00pm - via Zoom - Please come and join Danielle & Perm for their latest meet up where we are delighted to welcome our guest speaker Tilly Dowler, The Blind Stylist.
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.